Bahige M Baroudy

Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

Anandan Palani, Christoph Seibert, John P. Moore, 2006, Virology.

Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor

Robyn L Stanfield, Ian A Wilson, B. Korber, 2004, Journal of Virology.

Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.

William J Greenlee, Anandan Palani, W. Greenlee, 2003, Bioorganic & medicinal chemistry letters.

The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

Rong Liu, G. Reyes, B. Malcolm, 2003, Virology.

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonis

J. Lachowicz, K. Cox, G. Varty, 2004, Journal of medicinal chemistry.